ERT, a global leader in clinical endpoint data solutions, has announced the close of its merger with Bioclinica, a technological and scientific leader in clinical imaging. This combination creates the global leader in clinical trial endpoint technology and leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with an unrelenting focus on customer service.
Latham & Watkins LLP represented a consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company ERT in the transaction with a corporate deal team led by New York partner David Beller and London and Paris partner Thomas Forschbach.
